Kvantra
Kvantra
Log inSign up for Free
Log inSign up for Free
Stock profile

Design Therapeutics, Inc.(DSGN)

Country: United States of AmericaSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
Watchlist
Sign up to track this stock
P/E TTM
N/A
History
P/E NTM
N/A
Market cap
886.26M
Currency USD
KvantraRanki77
Value53
Quality99
Momentum85
Current price
14.39-1.84%
Benchmarks

No price history available.

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m000000N/AN/A
Operating profit$mLockedLockedLockedLockedLockedLockedLockedLocked
Net profit$m-8-36-63-67-50-70N/AN/A
EPS reported$LockedLockedLockedLockedLockedLockedLockedLocked
Operating cashflow per share$LockedLockedLockedLockedLockedLockedLockedLocked
Capex per share$LockedLockedLockedLockedLockedLockedLockedLocked
FCF per share$LockedLockedLockedLockedLockedLockedLockedLocked
Free cash flow$mLockedLockedLockedLockedLockedLockedLockedLocked
Net debt$mLockedLockedLockedLockedLockedLockedLockedLocked
Book value equity$mLockedLockedLockedLockedLockedLockedLockedLocked
Book value per share$LockedLockedLockedLockedLockedLockedLockedLocked
Number of sharesmLockedLockedLockedLockedLockedLockedLockedLocked
DPS (TTM paid)$LockedLockedLockedLockedLockedLockedLockedLocked

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E LTMxLockedLockedLockedLockedLockedLockedLockedLocked
P/B LTMxLockedLockedLockedLockedLockedLockedLockedLocked
P/S LTMxLockedLockedLockedLockedLockedLockedLockedLocked
P/FCF LTMxLockedLockedLockedLockedLockedLockedLockedLocked
EV/EBITDA LTMxLockedLockedLockedLockedLockedLockedLockedLocked
EV/Sales LTMxLockedLockedLockedLockedLockedLockedLockedLocked
Earnings Yield LTM%LockedLockedLockedLockedLockedLockedLockedLocked
FCF Yield%LockedLockedLockedLockedLockedLockedLockedLocked
Quality
ROE%LockedLockedLockedLockedLockedLockedLockedLocked
ROIC%LockedLockedLockedLockedLockedLockedLockedLocked
Operating margin%LockedLockedLockedLockedLockedLockedLockedLocked
Gross margin%LockedLockedLockedLockedLockedLockedLockedLocked
FCF/Sales%LockedLockedLockedLockedLockedLockedLockedLocked
Growth and momentum
EPS Growth YoY%LockedLockedLockedLockedLockedLockedLockedLocked
Sales Growth YoY%LockedLockedLockedLockedLockedLockedLockedLocked
Net Income Growth YoY%LockedLockedLockedLockedLockedLockedLockedLocked
FCF Growth%LockedLockedLockedLockedLockedLockedLockedLocked
Operating Profit Growth%LockedLockedLockedLockedLockedLockedLockedLocked
Dividend and capital structure
Dividend Yield%LockedLockedLockedLockedLockedLockedLockedLocked
Dividend Growth%LockedLockedLockedLockedLockedLockedLockedLocked
Payout Ratio%LockedLockedLockedLockedLockedLockedLockedLocked
FCF/DebtxLockedLockedLockedLockedLockedLockedLockedLocked
Net Debt/EBITDAxLockedLockedLockedLockedLockedLockedLockedLocked
EBIT/Net interestxLockedLockedLockedLockedLockedLockedLockedLocked
Net debt/market cap%LockedLockedLockedLockedLockedLockedLockedLocked
Net debt/Equity%LockedLockedLockedLockedLockedLockedLockedLocked
Gross debt/equity%LockedLockedLockedLockedLockedLockedLockedLocked

Price target estimates

Low estimateLocked
High estimateLocked
Price consensusLocked
Last year average price targetLocked
Current price14.39
Return PotentialLocked

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Locked
Buy
Locked
Hold
Locked
Sell
Locked
Strong Sell
Locked
Number of covering analystsLocked

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-scoreLockedLockedLocked
Environmental scoreLockedLockedLocked
Social scoreLockedLockedLocked
Governance scoreLockedLockedLocked
Risk ratingLockedLockedLocked

Company overview

Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.

SectorHealthcare
IndustryBiotechnology
CountryUnited States of America
Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Design Therapeutics, Inc. (DSGN)

DSGN · NASDAQ · Healthcare
14.39-1.84%
Sign up to track this stock

No price history available.

KvantraRank77
P/E TTMN/A
P/E NTMN/A
Market cap886.26M
KvantraRank77 / 100
Value
53
Quality
99
Momentum
85
Financialsin USD
20242025TTM2026E
Analyst target
ConsensusLocked
Current14.39
UpsideLocked
LockedLocked
Price consensusLocked
Last year average price targetLocked
Current price14.39
Return PotentialLocked

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Locked
Buy
Locked
Hold
Locked
Sell
Locked
Strong Sell
Locked

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-scoreLockedLockedLocked
Environmental scoreLockedLockedLocked
Social scoreLockedLockedLocked
Governance scoreLockedLockedLocked
Risk ratingLockedLockedLocked
About

Design Therapeutics, Inc. is a biopharmaceutical company in the preclinical phase that focuses on creating treatments for genetic conditions stemming from nucleotide repeat expansions. Its current pipeline targets Friedreich's Ataxia (FA), a severe, progressive, monogenic, and autosomal recessive disease. FA primarily impairs mitochondrial function across various organ systems, resulting in neurological, cardiac, and metabolic complications. Another significant area of development is Myotonic Dystrophy Type-1 (DM1). This is a progressive, dominantly inherited monogenic neuromuscular illness that impacts skeletal muscle, the heart, brain, and other bodily systems. Beyond these, the company is advancing its GeneTAC product candidate platform to address an array of other monogenic conditions caused by nucleotide repeat expansions. These include Fragile X syndrome, various spinocerebellar ataxias, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, Huntington's disease, and spinobulbar muscular atrophy. Established in 2017, Design Therapeutics, Inc. maintains its headquarters in Carlsbad, California.

SectorHealthcare
IndustryBiotechnology
CountryUnited States of America
Trades inUSD
Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data for this stock

Unlimited access to every company

See plans

Unlock all fundamental data for this stock

Unlimited access to every company

See plans